Invention Grant
US09458179B2 Quinuclidine, 1-azabicyclo[2.2.1]heptane, 1-azabicyclo [3.2.1]octane, and 1-azabicyclo[3.2.2]nonane compounds as alpha-7 nicotinic acetylcholine receptor ligands
有权
奎宁环，1-氮杂双环[2.2.1]庚烷，1-氮杂双环[3.2.1]辛烷和1-氮杂双环[3.2.2]壬烷化合物，为α-7烟碱乙酰胆碱受体配体
![Quinuclidine, 1-azabicyclo[2.2.1]heptane, 1-azabicyclo [3.2.1]octane, and 1-azabicyclo[3.2.2]nonane compounds as alpha-7 nicotinic acetylcholine receptor ligands](/docs/US/2016-10-04/US09458179B2/abs.jpg.600x600.jpg)
- Patent Title: Quinuclidine, 1-azabicyclo[2.2.1]heptane, 1-azabicyclo [3.2.1]octane, and 1-azabicyclo[3.2.2]nonane compounds as alpha-7 nicotinic acetylcholine receptor ligands
- Patent Title (中): 奎宁环，1-氮杂双环[2.2.1]庚烷，1-氮杂双环[3.2.1]辛烷和1-氮杂双环[3.2.2]壬烷化合物，为α-7烟碱乙酰胆碱受体配体
-
Application No.: US14400948Application Date: 2013-05-20
-
Publication No.: US09458179B2Publication Date: 2016-10-04
- Inventor: Matthew D. Hill , Haiquan Fang
- Applicant: BRISTOL-MYERS SQUIBB COMPANY
- Applicant Address: US NJ Princeton
- Assignee: Bristol-Myers Squibb Company
- Current Assignee: Bristol-Myers Squibb Company
- Current Assignee Address: US NJ Princeton
- Agent James Epperson
- International Application: PCT/US2013/041783 WO 20130520
- International Announcement: WO2013/177024 WO 20131128
- Main IPC: C07D519/00
- IPC: C07D519/00 ; C07D471/20 ; C07D453/02 ; C07D498/20
![Quinuclidine, 1-azabicyclo[2.2.1]heptane, 1-azabicyclo [3.2.1]octane, and 1-azabicyclo[3.2.2]nonane compounds as alpha-7 nicotinic acetylcholine receptor ligands](/abs-image/US/2016/10/04/US09458179B2/abs.jpg.150x150.jpg)
Abstract:
The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic α7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.
Public/Granted literature
Information query
